ASCO 2022 Conference Coverage


 

ASCO 2022 Birtamimab in Pts With Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study

614 views
June 14, 2022
Comments 0
Login to view comments. Click here to Login